The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Prospective Multi-center Phase III Randomized Controlled Trial
Official Title: Nedaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma:A Prospective Multi-center Phase III Randomized Controlled Trial
Study ID: NCT02607592
Brief Summary: The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value(OTV)on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Sun Yat-sen University of cancer center, Guangzhou, Guangdong, China
Name: li-kun Chen, Doctor
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR